Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Lung Cancer

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 65 articles:
HTML format



Single Articles


    October 2021
  1. BOOSMAN RJ, Dorlo TPC, de Rouw N, Burgers JA, et al
    Toxicity of pemetrexed during renal impairment explained-Implications for safe treatment.
    Int J Cancer. 2021;149:1576-1584.
    PubMed     Abstract available


  2. MIURA A, Yamada D, Nakamura M, Tomida S, et al
    Oncogenic potential of human pluripotent stem cell-derived lung organoids with HER2 overexpression.
    Int J Cancer. 2021;149:1593-1604.
    PubMed     Abstract available


    September 2021
  3. HUANG Y, Soon YY, Aminkeng F, Tay SH, et al
    Risk factors for Immune-related Adverse Events from anti-PD-1 or anti PD-L1 treatment in an Asian cohort of non-small cell lung cancer patients.
    Int J Cancer. 2021 Sep 25. doi: 10.1002/ijc.33822.
    PubMed     Abstract available


  4. HUANG CH, Ju JS, Chiu TH, Huang AC, et al
    Afatinib treatment in a large real-world cohort of non-small cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation.
    Int J Cancer. 2021 Sep 24. doi: 10.1002/ijc.33821.
    PubMed     Abstract available


    August 2021
  5. JI M, Du L, Ma Z, Xie J, et al
    Circulating C-reactive protein increases lung cancer risk: results from a prospective cohort of UK Biobank.
    Int J Cancer. 2021 Aug 27. doi: 10.1002/ijc.33780.
    PubMed     Abstract available


  6. RISSANEN E, Heikkinen S, Seppa K, Ryynanen H, et al
    Incidence trends and risk factors of lung cancer in never smokers - Pooled analyses of seven cohorts.
    Int J Cancer. 2021 Aug 16. doi: 10.1002/ijc.33765.
    PubMed     Abstract available


  7. TANIGUCHI H, Natori Y, Miyagi Y, Hayashi K, et al
    Treatment of primary and metastatic breast and pancreatic tumors upon intravenous delivery of a PRDM14-specific chimeric siRNA/nanocarrier complex.
    Int J Cancer. 2021;149:646-656.
    PubMed     Abstract available


    July 2021
  8. ROSIGKEIT S, Kruchem M, Thies D, Kreft A, et al
    Definitive evidence for Club cells as progenitors for mutant Kras/Trp53-deficient lung cancer.
    Int J Cancer. 2021 Jul 31. doi: 10.1002/ijc.33756.
    PubMed     Abstract available


  9. BUERGY D, Wurschmidt F, Gkika E, Horner-Rieber J, et al
    Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysis.
    Int J Cancer. 2021;149:358-370.
    PubMed     Abstract available


    June 2021
  10. DOMINE GOMEZ M, Csoszi T, Jaal J, Kudaba I, et al
    Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer.
    Int J Cancer. 2021 Jun 10. doi: 10.1002/ijc.33705.
    PubMed     Abstract available


    May 2021
  11. MU R, Liu H, Luo S, Patz EF Jr, et al
    Genetic variants of CHEK1, PRIM2 and CDK6 in the mitotic phase-related pathway are associated with nonsmall cell lung cancer survival.
    Int J Cancer. 2021 May 31. doi: 10.1002/ijc.33702.
    PubMed     Abstract available


  12. YU X, Sheng J, Pan G, Fan Y, et al
    Real-World Utilization of EGFR TKIs and Prognostic Factors for Survival in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases.
    Int J Cancer. 2021 May 10. doi: 10.1002/ijc.33677.
    PubMed     Abstract available


  13. XIA Y, Ying S, Jin R, Wu H, et al
    Application of a classifier combining bronchial transcriptomics and chest CT features facilitates the diagnostic evaluation of lung cancer in smokers and non-smokers.
    Int J Cancer. 2021 May 8. doi: 10.1002/ijc.33675.
    PubMed     Abstract available


  14. HAMFJORD J, Guren TK, Glimelius B, Sorbye H, et al
    Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS- or BRAF-mutated metastatic colorectal cancer.
    Int J Cancer. 2021 May 7. doi: 10.1002/ijc.33672.
    PubMed     Abstract available


  15. MORGAN E, Arnold M, Rutherford M, Bardot A, et al
    The impact of reclassifying cancers of unspecified histology on international differences in survival for small cell and non-small cell lung cancer (ICBP SurvMark-2 project).
    Int J Cancer. 2021 May 1. doi: 10.1002/ijc.33620.
    PubMed     Abstract available


    April 2021
  16. HENNESSY M, Wahba A, Felix K, Cabrera M, et al
    Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma.
    Int J Cancer. 2021;148:1928-1937.
    PubMed     Abstract available


  17. CAI L, Chen Y, Tong X, Wu X, et al
    The genomic landscape of young and old lung cancer patients highlights age-dependent mutation frequencies and clinical actionability in young patients.
    Int J Cancer. 2021 Apr 2. doi: 10.1002/ijc.33583.
    PubMed     Abstract available


  18. HUANG RSP, Haberberger J, Sokol E, Schrock AB, et al
    Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases.
    Int J Cancer. 2021;148:1778-1788.
    PubMed     Abstract available


  19. SHI Z, Wei J, Na R, Resurreccion WK, et al
    Cystic fibrosis F508del carriers and cancer risk: Results from the UK Biobank.
    Int J Cancer. 2021;148:1658-1664.
    PubMed     Abstract available


    March 2021
  20. TEN HAAF K, van der Aalst CM, de Koning HJ, Kaaks R, et al
    Personalising lung cancer screening: an overview of risk-stratification opportunities and challenges.
    Int J Cancer. 2021 Mar 30. doi: 10.1002/ijc.33578.
    PubMed     Abstract available


  21. TAKADA K, Shimokawa M, Takamori S, Shimamatsu S, et al
    Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with non-small cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting.
    Int J Cancer. 2021 Mar 15. doi: 10.1002/ijc.33557.
    PubMed     Abstract available


  22. LAUTZ TB, Farooqui Z, Jenkins T, Heaton TE, et al
    Thoracoscopy vs thoracotomy for the management of metastatic osteosarcoma: A Pediatric Surgical Oncology Research Collaborative Study.
    Int J Cancer. 2021;148:1164-1171.
    PubMed     Abstract available


    February 2021
  23. LOW JL, Huang Y, Sooi K, Ang Y, et al
    Low dose pembrolizumab in the treatment of advanced non-small cell lung cancer.
    Int J Cancer. 2021 Feb 26. doi: 10.1002/ijc.33534.
    PubMed     Abstract available


  24. KRILAVICIUTE A, Brenner H
    Low positive predictive value of computed tomography screening for lung cancer irrespective of commonly employed definitions of target population.
    Int J Cancer. 2021 Feb 26. doi: 10.1002/ijc.33522.
    PubMed     Abstract available


  25. HATA A, Nakajima T, Matsusaka K, Fukuyo M, et al
    Genetic alterations in squamous cell lung cancer associated with idiopathic pulmonary fibrosis.
    Int J Cancer. 2021 Feb 3. doi: 10.1002/ijc.33499.
    PubMed     Abstract available


  26. HEIDRICH I, Ackar L, Mossahebi Mohammadi P, Pantel K, et al
    Liquid biopsies: Potential and challenges.
    Int J Cancer. 2021;148:528-545.
    PubMed     Abstract available


    January 2021
  27. LILJEDAHL H, Karlsson A, Oskarsdottir GN, Salomonsson A, et al
    A gene expression-based single sample predictor of lung adenocarcinoma molecular subtype and prognosis.
    Int J Cancer. 2021;148:238-251.
    PubMed     Abstract available


    December 2020
  28. DANIEL D, Kuchava V, Bondarenko I, Ivashchuk O, et al
    Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled phase II trial.
    Int J Cancer. 2020 Dec 21. doi: 10.1002/ijc.33453.
    PubMed     Abstract available


  29. ZHU J, Smith-Warner SA, Yu D, Zhang X, et al
    Associations of coffee and tea consumption with lung cancer risk.
    Int J Cancer. 2020 Dec 16. doi: 10.1002/ijc.33445.
    PubMed     Abstract available


    November 2020
  30. WU YL, Zhang L, Fan Y, Zhou J, et al
    Randomized Clinical Trial of Pembrolizumab Versus Chemotherapy for Previously Untreated Chinese Patients With PD-L1-Positive Locally Advanced or Metastatic Non-Small-Cell Lung Cancer: KEYNOTE-042 China Study.
    Int J Cancer. 2020 Nov 24. doi: 10.1002/ijc.33399.
    PubMed     Abstract available


  31. JIN K, Hung RJ, Thomas S, Le Marchand L, et al
    Hormonal factors in association with lung cancer among Asian women: a pooled analysis from the International Lung Cancer Consortium.
    Int J Cancer. 2020 Nov 19. doi: 10.1002/ijc.33405.
    PubMed     Abstract available


  32. GIRON P, Eggermont C, Noeparast A, Vandenplas H, et al
    Targeting USP13 mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in Non-Small Cell Lung Cancer.
    Int J Cancer. 2020 Nov 19. doi: 10.1002/ijc.33404.
    PubMed     Abstract available


  33. MCGUIRE JJ, Nerlakanti N, Lo CH, Tauro M, et al
    Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma.
    Int J Cancer. 2020;147:2811-2823.
    PubMed     Abstract available


  34. HAAKENSEN VD, Khadse A, Sandhu V, Halvorsen AR, et al
    Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy.
    Int J Cancer. 2020;147:2957-2966.
    PubMed     Abstract available


  35. XUE R, Sheng Y, Duan X, Yang Y, et al
    Tie2-expressing monocytes as a novel angiogenesis-related cellular biomarker for non-small cell lung cancer.
    Int J Cancer. 2020 Nov 5. doi: 10.1002/ijc.33381.
    PubMed     Abstract available


  36. MA J, Klemm J, Gerardo-Ramirez M, Frappart L, et al
    Cluster of differentiation 44 promotes osteosarcoma progression in mice lacking the tumor suppressor Merlin.
    Int J Cancer. 2020;147:2564-2577.
    PubMed     Abstract available


  37. CHENG C, Zhao Y, Schaafsma E, Weng YL, et al
    An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.
    Int J Cancer. 2020;147:2621-2633.
    PubMed     Abstract available


    October 2020
  38. THURMAIER J, Heinemann V, Engel J, Schubert-Fritschle G, et al
    Patients with colorectal cancer and brain metastasis: The relevance of extracranial metastatic patterns predicting time intervals to first occurrence of intracranial metastasis and survival.
    Int J Cancer. 2020 Oct 28. doi: 10.1002/ijc.33364.
    PubMed     Abstract available


  39. WAH W, Stirling RG, Ahern S, Earnest A, et al
    Influence of Timeliness and Receipt of First Treatment on Geographic Variation in Non-small Cell Lung Cancer Mortality.
    Int J Cancer. 2020 Oct 12. doi: 10.1002/ijc.33343.
    PubMed     Abstract available


    September 2020
  40. GONZALEZ MALDONADO S, Motsch E, Trotter A, Kauczor HU, et al
    Overdiagnosis in lung cancer screening - estimates from the German Lung Cancer Screening Intervention Trial.
    Int J Cancer. 2020 Sep 15. doi: 10.1002/ijc.33295.
    PubMed     Abstract available


  41. SIRRI E, Kieschke J, Vohmann C, Katalinic A, et al
    Survival of malignant mesothelioma and other rare thoracic cancers in Germany and the United States: A population-based study.
    Int J Cancer. 2020;147:1548-1558.
    PubMed     Abstract available


  42. ENGLINGER B, Laemmerer A, Moser P, Kallus S, et al
    Lipid droplet-mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib.
    Int J Cancer. 2020;147:1680-1693.
    PubMed     Abstract available


  43. ZHOU W, Liu G, Hung RJ, Haycock PC, et al
    Causal Relationships between Body Mass Index, Smoking, and Lung Cancer: Univariable and Multivariable Mendelian Randomization.
    Int J Cancer. 2020 Sep 11. doi: 10.1002/ijc.33292.
    PubMed     Abstract available


  44. DUDNIK E, Moskovitz M, Agbarya A, Gottfried T, et al
    Alternative nivolumab duration and scheduling in advanced non-small cell lung cancer (aNSCLC): a real-world evidence.
    Int J Cancer. 2020 Sep 1. doi: 10.1002/ijc.33281.
    PubMed     Abstract available


    August 2020
  45. GRAU N, Scherer SD, Rothley M, Rosswag S, et al
    Spatiotemporally controlled induction of gene expression in vivo allows tracking the fate of tumor cells that traffic through the lymphatics.
    Int J Cancer. 2020;147:1190-1198.
    PubMed     Abstract available


  46. MENGONI M, Braun AD, Gaffal E, Tuting T, et al
    The aryl hydrocarbon receptor promotes inflammation-induced dedifferentiation and systemic metastatic spread of melanoma cells.
    Int J Cancer. 2020 Aug 13. doi: 10.1002/ijc.33252.
    PubMed     Abstract available


  47. YOO JE, Han K, Shin DW, Park SH, et al
    Conditional relative survival and competing mortality in patients who underwent surgery for lung cancer: a nationwide cohort study.
    Int J Cancer. 2020 Aug 1. doi: 10.1002/ijc.33239.
    PubMed     Abstract available


  48. WALPOLE E, Dunn N, Youl P, Harden H, et al
    Nonbreast cancer incidence, treatment received and outcomes: Are there differences in breast screening attendees versus nonattendees?
    Int J Cancer. 2020;147:856-865.
    PubMed     Abstract available


  49. VAN DER WILLIK KD, Ruiter R, van Rooij FJA, Verkroost-van Heemst J, et al
    Ascertainment of cancer in longitudinal research: The concordance between the Rotterdam Study and the Netherlands Cancer Registry.
    Int J Cancer. 2020;147:633-640.
    PubMed     Abstract available


  50. CARIOLI G, Bertuccio P, Malvezzi M, Rodriguez T, et al
    Cancer mortality predictions for 2019 in Latin America.
    Int J Cancer. 2020;147:619-632.
    PubMed     Abstract available


    June 2020
  51. WU D, Nie J, Hu W, Dai L, et al
    A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer.
    Int J Cancer. 2020 Jun 18. doi: 10.1002/ijc.33161.
    PubMed     Abstract available


  52. URAKAWA H, Ando Y, Hase T, Kikumori T, et al
    Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study.
    Int J Cancer. 2020;146:3504-3515.
    PubMed     Abstract available


  53. DAGNINO S, Bodinier B, Grigoryan H, Rappaport SM, et al
    Agnostic Cys34-albumin adductomics and DNA methylation: Implication of N-acetylcysteine in lung carcinogenesis years before diagnosis.
    Int J Cancer. 2020;146:3294-3303.
    PubMed     Abstract available


  54. VELAZQUEZ-KRONEN R, Gilbert ES, Linet MS, Moysich KB, et al
    Lung cancer mortality associated with protracted low-dose occupational radiation exposures and smoking behaviors in U.S. radiologic technologists, 1983-2012.
    Int J Cancer. 2020 Jun 7. doi: 10.1002/ijc.33141.
    PubMed     Abstract available


  55. HOPKINS AM, Wagner J, Kichenadasse G, Modi N, et al
    Patient-reported outcomes as a prognostic marker of survival in patients with advanced non-small cell lung cancer treated with immunotherapy: PROs as a prognostic marker for immunotherapies.
    Int J Cancer. 2020 Jun 3. doi: 10.1002/ijc.33133.
    PubMed     Abstract available


  56. HOU HH, Pan HJ, Liao WY, Lee CH, et al
    Autophagy in fibroblasts induced by cigarette smoke extract promotes invasion in lung cancer cells.
    Int J Cancer. 2020 Jun 3. doi: 10.1002/ijc.33127.
    PubMed     Abstract available


    May 2020
  57. ZONNEVILLE J, Colligan S, Grant S, Miller A, et al
    Blockade of p38 kinase impedes the mobilization of protumorigenic myeloid populations to impact breast cancer metastasis.
    Int J Cancer. 2020 May 25. doi: 10.1002/ijc.33050.
    PubMed     Abstract available


  58. CAI H, Sobue T, Kitamura T, Ishihara J, et al
    Association between Meat and Saturated Fatty Acid Intake and Lung Cancer Risk: The Japan Public Health Center-based Prospective Study.
    Int J Cancer. 2020 May 22. doi: 10.1002/ijc.33112.
    PubMed     Abstract available


  59. HE Q, Li X, He L, Li Y, et al
    Pericyte dysfunction due to Shb gene deficiency increases B16F10 melanoma lung metastasis.
    Int J Cancer. 2020 May 22. doi: 10.1002/ijc.33110.
    PubMed     Abstract available


  60. TAKAMORI S, Takada K, Shimokawa M, Matsubara T, et al
    Predictive and prognostic impact of primary tumor-bearing lobe in non-small cell lung cancer patients treated with anti-PD-1 therapy.
    Int J Cancer. 2020 May 1. doi: 10.1002/ijc.33030.
    PubMed     Abstract available


  61. DONG S, Ruiz-Calderon B, Rathinam R, Eastlack S, et al
    Knockout model reveals the role of Nischarin in mammary gland development, breast tumorigenesis and response to metformin treatment.
    Int J Cancer. 2020;146:2576-2587.
    PubMed     Abstract available


  62. BERGQVIST M, Christensen HN, Wiklund F, Bergstrom S, et al
    Real world utilization of EGFR TKIs and prognostic factors for survival in NSCLC during 2010-2016 in Sweden: A nationwide observational study.
    Int J Cancer. 2020;146:2510-2517.
    PubMed     Abstract available


    March 2020
  63. FU F, Zhang Y, Gao Z, Zhao Y, et al
    Development and Validation of a Five-Gene Model to Predict Postoperative Brain Metastasis in Operable Lung Adenocarcinoma.
    Int J Cancer. 2020 Mar 17. doi: 10.1002/ijc.32981.
    PubMed     Abstract available


  64. KATO M, Onoyama I, Yoshida S, Cui L, et al
    Dual specificity phosphatase 6 plays a critical role in the maintenance of a cancer stem-like cell phenotype in human endometrial cancer.
    Int J Cancer. 2020 Mar 11. doi: 10.1002/ijc.32965.
    PubMed     Abstract available


    January 2020
  65. TRICKEY A, May MT, Gill MJ, Grabar S, et al
    Cause-specific mortality after diagnosis of cancer among HIV-positive patients: a collaborative analysis of cohort studies.
    Int J Cancer. 2020 Jan 31. doi: 10.1002/ijc.32895.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: